

1 Dalmore Drive,  
Scoresby,  
Victoria 3179  
AUSTRALIA  
T: +61 (0)3 9763-1287  
F: +61 (0)3 9763-2817  
[www.generabiosystems.com](http://www.generabiosystems.com)

31 January 2019

Dear Optionholder

**Notification of non-renounceable entitlement offer**

Genera Biosystems Limited (**Company**) has announced to ASX Limited (**ASX**) a pro-rata non-renounceable entitlement offer on the basis of four (4) fully paid ordinary shares for every five (5) ordinary shares held by Shareholders registered at 7.00 pm (AEDT) on Wednesday, 6 February 2019 (**Record Date**) at an issue price of \$0.13 (13 cents) (**Entitlement Offer**).

The Entitlement Offer will be offered to shareholders registered on the Record Date with a registered address in Australia or New Zealand (**Eligible Shareholder**).

Under the terms of the options you currently hold, there is no entitlement to participate in the Entitlement Offer, unless you exercise your options and are entered onto the register as an Eligible Shareholder on or before the Record Date. The purpose of this letter is to give you that notice in order to permit you to participate in the Entitlement Offer, should you wish to do so.

If you wish to participate in the Entitlement Offer (in respect of your options), you will need to exercise all or part of your options in accordance with their terms at least 1 day prior to **6 February 2019**.

Pursuant to section 713 of the *Corporations Act* 2001, the Company has today lodged a Prospectus with ASX, which is available via the Company's ASX announcements page on the ASX's website at [www.asx.com.au](http://www.asx.com.au). The Prospectus will be dispatched to eligible shareholders of the Company who are registered on the share register on the Record Date at 7.00pm (AEDT) on Wednesday, 6 February 2019 and who have their registered address in Australia or New Zealand.

If you do not wish to participate in the Entitlement Offer (in respect of your options) you do not need to take any action. Before deciding whether to exercise all or any of your options, you should consider the Prospectus. If in any doubt, you should consult with your professional advisor.

Should you have any queries in relation to this matter, please do not hesitate to contact the Company on +61 3 9763 1287.

Yours faithfully



Richard Hannebery  
Chief Executive Officer